Literature DB >> 10555611

Prognostic factors correlated with survival in AIDS patients.

S Casari1, A Donisi, G Paraninfo, D Tomasoni, L Palvarini, P Nasta, A Bergamasco, G P Cadeo, G Carosi.   

Abstract

The authors present the AIDS cases (CDC '93) observed in Brescia from 1983 to 1994. They observed 1189 subjects (M 84%, F 16%) with a mean age of 32.7 years (intra-venous drug users 75.1%, heterosexuals 14%, homosexuals 9.6%). The mean survival observed was 56.7 weeks from the diagnosis of AIDS (mortality per year 78%). The most frequent AIDS-defining events were Visceral Candidiasis, P. carinii Pneumonia (PCP) and Neurotoxoplasmosis, while the longest and shortest mean survival was for Kaposi's Sarcoma (89 weeks) and Wasting Syndrome (8.4). The mean value of CD4+ lymphocyte counts on AIDS diagnosis was 72.6/microl (1166 cases) and the highest and lowest were in non-Hodgkin's Lymphoma (NHL; 147.6/microl) and Cryptosporidiosis (18.8/microl). Antiretroviral therapy had been given for at least a month in 41.4% subjects (mean treatment duration of 74.8 weeks). The Cox model has demonstrated the favourable effect on survival of high CD4+ lymphocyte counts on diagnosis, antiretroviral therapy, the diagnosis of Tuberculosis (TBC) and PCP as initial markers and the diagnosis of TBC, PCP or Cytomegalovirus infection (CMV) during the entire clinical evolution. Moreover, the unfavourable effect of high age, diagnosis of Progressive Multifocal Leucoencephalopathy (PML), Wasting Syndrome and NHL as initial markers and diagnosis of PML or NHL in any moment of the disease has been demonstrated.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10555611     DOI: 10.1023/a:1007676625117

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  17 in total

1.  Prognostic indicators for development of AIDS among intravenous drug users.

Authors:  A Muñoz; D Vlahov; L Solomon; J B Margolick; J C Bareta; S Cohn; J Astemborski; K E Nelson
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1992

2.  The effect of CMV infection on progression of human immunodeficiency virus disease is a cohort of haemophilic men followed for up to 13 years from seroconversion.

Authors:  C A Sabin; A N Phillips; C A Lee; G Janossy; V Emery; P D Griffiths
Journal:  Epidemiol Infect       Date:  1995-04       Impact factor: 2.451

3.  Prognostic factors in human immunodeficiency virus-positive patients with a CD4+ lymphocyte count < 50/microL.

Authors:  E G Apolonio; D R Hoover; Y He; A J Saah; D W Lyter; R Detels; R A Kaslow; J P Phair
Journal:  J Infect Dis       Date:  1995-04       Impact factor: 5.226

4.  Effect of sex, age and transmission category on the progression to AIDS and survival of zidovudine-treated symptomatic patients.

Authors:  S Vella; M Giuliano; M Floridia; A Chiesi; C Tomino; A Seeber; S Barcherini; R Bucciardini; S Mariotti
Journal:  AIDS       Date:  1995-01       Impact factor: 4.177

5.  The role of initial AIDS-defining illness in survival following AIDS.

Authors:  K Luo; M Law; J M Kaldor; A M McDonald; D A Cooper
Journal:  AIDS       Date:  1995-01       Impact factor: 4.177

6.  Survival differences in patients with AIDS.

Authors:  G H Friedland; B Saltzman; J Vileno; K Freeman; L K Schrager; R S Klein
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1991

7.  The effect of the interaction of acyclovir with zidovudine on progression to AIDS and survival. Analysis of data in the Multicenter AIDS Cohort Study.

Authors:  D S Stein; N M Graham; L P Park; D R Hoover; J P Phair; R Detels; M Ho; A J Saah
Journal:  Ann Intern Med       Date:  1994-07-15       Impact factor: 25.391

8.  The predictive value of T cell function in vitro and pre-AIDS zidovudine use for survival after AIDS diagnosis in a cohort of homosexual men in Amsterdam.

Authors:  P J Bindels; A Krol; M Roos; J Veenstra; J A van den Hoek; F Miedema; R A Coutinho
Journal:  J Infect Dis       Date:  1995-07       Impact factor: 5.226

9.  Survival from early, intermediate, and late stages of HIV infection.

Authors:  C Enger; N Graham; Y Peng; J S Chmiel; L A Kingsley; R Detels; A Muñoz
Journal:  JAMA       Date:  1996-05-01       Impact factor: 56.272

10.  The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1.

Authors:  J L Fahey; J M Taylor; R Detels; B Hofmann; R Melmed; P Nishanian; J V Giorgi
Journal:  N Engl J Med       Date:  1990-01-18       Impact factor: 91.245

View more
  1 in total

1.  Clinical, immunological and virological evolution in patients with CD4 T-cell count above 500/mm3: is there a benefit to treat with highly active antiretroviral therapy (HAART)?

Authors:  Lionel Piroth; Christine Binquet; Marielle Buisson; Evelyne Kohli; Michel Duong; Michèle Grappin; Michal Abrahamowicz; Catherine Quantin; Henri Portier; Pascal Chavanet
Journal:  Eur J Epidemiol       Date:  2004       Impact factor: 8.082

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.